Singular Genomics Revenue vs. Cash And Equivalents
| OMICDelisted Stock | USD 20.01 0.00 0.00% |
For Singular Genomics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Singular Genomics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Singular Genomics Systems utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Singular Genomics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Singular Genomics Systems over time as well as its relative position and ranking within its peers.
Singular |
Singular Genomics Systems Cash And Equivalents vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Singular Genomics's current stock value. Our valuation model uses many indicators to compare Singular Genomics value to that of its competitors to determine the firm's financial worth. Singular Genomics Systems is rated below average in revenue category among its peers. It is considered to be number one stock in cash and equivalents category among its peers creating about 98.93 of Cash And Equivalents per Revenue. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Singular Genomics' earnings, one of the primary drivers of an investment's value.Singular Revenue vs. Competition
Singular Genomics Systems is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is now estimated at about 4.61 Billion. Singular Genomics adds roughly 2.91 Million in revenue claiming only tiny portion of equities under Health Care industry.
Singular Cash And Equivalents vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Singular Genomics |
| = | 2.91 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Singular Genomics |
| = | 287.98 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Singular Cash And Equivalents Comparison
Singular Genomics is currently under evaluation in cash and equivalents category among its peers.
Singular Genomics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Singular Genomics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Singular Genomics will eventually generate negative long term returns. The profitability progress is the general direction of Singular Genomics' change in net profit over the period of time. It can combine multiple indicators of Singular Genomics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California. Singular Genomics operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 248 people.
Singular Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Singular Genomics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Singular Genomics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Singular Genomics' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Singular Genomics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run USA ETFs Now
Use Investing Themes to Complement your Singular Genomics position
In addition to having Singular Genomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Furniture Thematic Idea Now
Furniture
Companies producing and selling home and office furniture. The Furniture theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Furniture Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Singular Stock
If you are still planning to invest in Singular Genomics Systems check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Singular Genomics' history and understand the potential risks before investing.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Commodity Directory Find actively traded commodities issued by global exchanges |